Liposomes as Safe Carriers of Drugs and Vaccines

Alving, Carl R.

doi:10.1007/978-3-642-48391-2_23

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes as carriers of vaccines and drugs are safe [ 45 ]. Liposome vaccine delivery provides more efficacy and safer vaccine formulation in the development of a vaccine for human use[ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model

et al. 2017

View full text Add to dashboard Cite

One of the challenging issues in vaccine development is peptide and adjuvant delivery into target cells. In this study, we developed a vaccine and therapeutic delivery system to increase cytotoxic T lymphocyte (CTL) response against a breast cancer model overexpressing HER2/neu.Gp2, a HER2/neu-derived peptide, was conjugated to Maleimide-mPEG2000-DSPE micelles and post inserted into liposomes composed of DMPC, DMPG phospholipids, and fusogenic lipid dioleoylphosphatidylethanolamine (DOPE) containing monophosphoryl lipid A (MPL) adjuvant (DMPC-DMPG-DOPE-MPL-Gp2). BALB/c mice were immunized with different formulations and the immune response was evaluated in vitro and in vivo. ELISpot and intracellular cytokine analysis by flow cytometry showed that the mice vaccinated with Lip-DOPE-MPL-GP2 incited the highest number of IFN-γ+ in CD8+ cells and CTL response. The immunization led to lower tumor sizes and longer survival time compared to the other groups of mice immunized and treated with the Lip-DOPE-MPL-GP2 formulation in both prophylactic and therapeutic experiments. These results showed that co-formulation of DOPE and MPL conjugated with GP2 peptide not only induces high antitumor immunity but also enhances therapeutic efficacy in TUBO mice model. Lip-DOPE-MPL-GP2 formulation could be a promising vaccine and a therapeutic delivery system against HER2 positive cancers and merits further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model

et al. 2017

View full text Add to dashboard Cite

show abstract

“…According to this hypothesis, liposomal antigen can be immunologically presented by macrophages as an endosomal degradation product through interaction of peptide with MHC molecules, either by fusion of endosomal membranes with vesicles containing empty MHC molecules (pathway A in FIG. 2) or by escape of lipidpeptide complexes into cytoplasm, followed by uptake by fusion with the Golgi ap- paratus where interaction with M H C I I molecules takes place (pathway B in FIG. 2).…”

Section: Class Iz Mhc P a T H A Ymentioning

confidence: 99%

Liposomal Vaccines: Clinical Status and Immunological Presentation for Humoral and Cellular Immunity

Alving

1995

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

Liposomes have been proposed as vehicles for vaccines against parasitic and viral illnesses. Experimental vaccines against malaria, HIV, hepatitis A, and influenza virus have been shown to be safe and highly immunogenic in several human trials. Analysis of the intracellular trafficking patterns of liposomal antigen reveals that after being phagocytosed by macrophages, liposomal antigen readily escapes from endosomes into the cytoplasm of the macrophages. It is proposed that liposomal peptide antigen can enter either the Golgi apparatus or the endoplasmic reticulum and thereby interact with MHC class II or class I molecules. The intracellular cytoplasmic trafficking patterns of liposomal antigens raise the possibility that liposomes may have utility in human vaccines for induction of either humoral immunity or cytotoxic T lymphocytes.

show abstract

Liposomes as Safe Carriers of Drugs and Vaccines

Cited by 2 publications

References 34 publications

Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model

Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model

Liposomal Vaccines: Clinical Status and Immunological Presentation for Humoral and Cellular Immunity

Contact Info

Product

Resources

About